Matrix Factorization Probability Estimation for Drug-Adverse Event Ranking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting drug-adverse event associations do not effectively utilize hidden patterns in literature text and struggle with ranking and prioritizing relationships between drugs and adverse events, leading to inefficient resource allocation and potential missed opportunities in drug development.
Innovation Solution
A computer-implemented method that uses matrix factorization to estimate expected scores and standard deviations, calculating Z-scores to determine the probability of relationships between drugs and adverse events, thereby providing a threshold for decision-making on resource allocation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If matrix factorization is used to predict drug-adverse event associations, then the ability to identify potential relationships is improved, but the reliability of ranking these relationships by likelihood is insufficient
Solution Approach 1:
The patent transforms the raw matrix factorization scores into probability estimates by changing the parameter representation from arbitrary scores to statistically meaningful probability values. This is achieved by calculating expected scores and standard deviations, then converting observed scores into probability estimates that reliably indicate the likelihood of drug-adverse event associations.
2Measurement precision
If traditional structure-activity relationship methods are used to identify drug side effects, then case-by-case analysis is possible, but the ability to analyze complex data patterns is limited
Solution Approach 1:
The patent creates a universal matrix factorization framework that can handle multiple types of relationships simultaneously (drug-drug, drug-adverse event, adverse event-adverse event) rather than analyzing each case separately. The matrix representation allows the same computational approach to be applied across diverse relationship types, enabling comprehensive pattern analysis while maintaining case-specific precision.
3Productivity
If matrix factorization produces raw scores for relationship ranking, then computational efficiency is improved, but the interpretability of results in terms of real-world likelihood is reduced
Solution Approach 1:
The patent introduces expected scores and standard deviations as intermediary statistical parameters that bridge the gap between raw matrix factorization outputs and interpretable probability estimates. These intermediaries preserve the computational efficiency of matrix factorization while enabling meaningful probability interpretations of the results.
4Device complexity
If no probability estimation is provided for matrix factorization results, then the method remains simple, but the ability to determine meaningful thresholds for resource allocation is lost
Solution Approach 1:
The patent performs preliminary calculation of expected scores and standard deviations before final result interpretation. By pre-computing these statistical parameters, the method establishes a foundation for threshold determination that makes resource allocation decisions more straightforward, allowing researchers to set meaningful cutoffs based on probability estimates rather than arbitrary score thresholds.
Data Source
AI summary
A method for ranking a relationship between drugs and adverse events includes creating a matrix of associations between a plurality of drugs and a plurality of adverse events and factoring the matrix of associates into a pair of matrix factors. The matrix factors, when multiplied, approximate the matrix of associations, and a product of the matrix factors is a matrix of observed scores. The method further includes determining, for each drug and adverse event pair in the matrix of observed scores, a z-score, an expected score for each drug and adverse event pair, and a standard deviation for each drug and adverse event pair, calculating a probability of a relationship between a drug and adverse event using the z-score for the drug and adverse event pair, and determining that the drug and adverse event are related, when the probability of a relationship is greater than a predetermined magnitude.